Encompass Health Surges 3.7% Pre-Market as Analysts Reiterate 'Buy' Ratings

Value Seekers Drive Pre-Market Rebound

Encompass Health Corp (EHC) is seeing a sharp move to the upside in pre-market trading this morning, gaining 3.72% to trade well ahead of the broader market. The move comes as a consensus of Wall Street brokerages reiterated their 'Buy' recommendations for the stock, signaling that the recent 8% pullback over the last 30 days may have created an attractive entry point for institutional investors.

According to market data released early Thursday, Encompass Health now carries a consensus 'Buy' rating from ten major research firms, with several analysts setting price targets significantly above current levels. Barclays recently adjusted its price objective to $153.00, maintaining an 'Overweight' rating, while other firms have highlighted the company's robust 2026 earnings guidance as a primary catalyst for long-term growth.

Expansion Strategy Fuels Optimism

Beyond the technical recovery, investor sentiment is being bolstered by the company's aggressive facility expansion. Encompass Health recently announced plans for a new 40-bed inpatient rehabilitation hospital in Bear, Delaware. This facility will focus on high-acuity, medically complex care, including specialized services like dialysis and advanced neurological rehabilitation. This move follows the successful opening of the Encompass Health Rehabilitation Hospital of Irmo in South Carolina earlier this month.

Management’s strategy to add 500 to 600 beds annually through 2027 is a core component of their growth narrative. By focusing on 'de novo' hospitals and small-format facilities in high-demand markets, EHC is positioning itself to capture the rising needs of an aging U.S. population. Analysts note that these new facilities typically reach 70% occupancy within their first year, providing a clear path to margin expansion.

Strong 2026 Outlook and Operational Efficiency

In early trading today, the market is also reacting to the company's reaffirmed 2026 financial guidance. Encompass Health expects full-year adjusted earnings per share (EPS) to fall between $5.81 and $6.10, on net operating revenues ranging from $6.37 billion to $6.47 billion. This outlook is supported by a significant reduction in premium labor spend, which was reportedly halved in 2025 compared to 2022 levels.

The company’s partnership with Palantir has also been cited by analysts as a key operational differentiator. The collaboration is aimed at streamlining clinical documentation and optimizing staffing models, which helps mitigate the labor shortage risks that have historically plagued the healthcare services sector. With a leverage ratio expected to drop to 1.8 times by the end of 2026, Encompass Health maintains the financial flexibility to continue its dividend program and share repurchases while funding its capital-intensive expansion.

Looking ahead, investors will be watching the Q1 2026 earnings report, scheduled for late April, to see if discharge growth can maintain its momentum despite recent unit closures. For now, the pre-market surge suggests that the market is looking past short-term volatility in favor of EHC’s dominant position in the inpatient rehabilitation space.